Option chain shows key data for Chemomab Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Chemomab Therapeutics.

Chemomab Therapeutics (NASDAQ:CMMB) Stock, Option Chain

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

bz_pharma_briefs

Biotech

News

Health Care

Trading Ideas

General

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab&#39;s OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Chemomab Therapeutics&#39; Touts Positive Data From Experimental Drug For Chronic Liver Disease

movers image

Intraday Update

Markets

Movers

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Offerings

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics Ltd

Press Releases

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Analyst Ratings

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Comments

Chemomab Therapeutics

Chemomab Therapeutics (CMMB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga